GO
Loading...

Gilead Sciences Inc

More

  • April 18- Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.

  • Several behemoths, including Apple, the largest U.S. company by market value, as well as Microsoft, McDonald's and AT&T, are due to report earnings.

  • *Google, IBM shares fall a day after posting earnings. NEW YORK, April 17- U.S. stocks ended a holiday-shortened week with mostly modest gains on Thursday, though the S&P 500 notched its biggest weekly advance since July as Morgan Stanley and General Electric rallied after strong results.

  • US STOCKS-Wall St edges higher during earnings flurry Thursday, 17 Apr 2014 | 1:40 PM ET

    *Google, IBM shares fall a day after posting earnings. NEW YORK, April 17- U.S. stocks advanced slightly in choppy trading on Thursday after three days of gains, as underwhelming results from tech bellwethers Google and IBM were offset by upbeat quarterly numbers, including those from Morgan Stanley and General Electric.

  • April 17- UnitedHealth Group Inc, the largest U.S. health insurer, said on Thursday it has spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc, a higher cost than it expected by "multiples," sending shares in the sector lower.

  • The $9.4 billion Fidelity Select Biotechnology Fund plunged 11.75 percent during the first 14 days of April. That put the fund near the bottom among nearly 3,800 U.S. mutual funds tracked by Lipper Inc. Only six funds performed worse, but they had less than $100 million in assets each.

  • UnitedHealth's 1Q profit tumbles 8 percent Thursday, 17 Apr 2014 | 6:27 AM ET

    UnitedHealth Group's first-quarter net income slid 8 percent as funding cuts to a key product and costs imposed by the health care overhaul dented the health insurer's performance.

  • Final Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 6:02 PM ET

    Amgen Inc. rose$. 54 or. 5 percent, to $115.54. Biogen Idec rose $5.99 or 2.1 percent, to $291.48. Celgene Corp. rose $2.02 or 1.4 percent, to $141.86.

  • Midday Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 1:30 PM ET

    Amgen Inc. rose$. 17 or. 1 percent, to $115.17. Biogen Idec rose $5.59 or 2.0 percent, to $291.08. Celgene Corp. rose $1.52 or 1.1 percent, to $141.36.

  • Early Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 10:27 AM ET

    Amgen Inc. fell$. 34 or. 3 percent, to $114.67. Biogen Idec rose $2.08 or. 7 percent, to $287.57. Celgene Corp. rose $1.35 or 1.0 percent, to $141.19.

  • NEW YORK, April 16- Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive.

  • Report: Prescription drug spending climbs in 2013 Tuesday, 15 Apr 2014 | 12:09 PM ET

    Total U.S. prescription drug spending climbed more than 3 percent last year, propelled in part by fewer patent expirations that would have allowed for cheaper generic alternatives, according to the data firm IMS Health. IMS Health also noted that 36 new treatments entered the market last year, including 10 for cancer.

  • April 15- Johnson& Johnson reported quarterly earnings well above expectations, as strong sales of new drugs offset weak demand for consumer products and medical devices, and the company slightly raised its full-year profit view. J&J on Tuesday said it earned $4.73 billion, or $1.64 per share, in the first quarter.

  • This strategy seems 'dumb as wood': Jim Cramer Tuesday, 15 Apr 2014 | 10:14 AM ET

    Paying up for high-growth stocks amid the stock market's ongoing rotation into safer bets has been a "true sin and dumber than wood," Jim Cramer says.

  • J&J beats forecasts, helped by new medicines Tuesday, 15 Apr 2014 | 10:06 AM ET

    Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.

  • Americans start spending on health care again Tuesday, 15 Apr 2014 | 7:06 AM ET

    Americans used more health services and spent more on prescription drugs in 2013, reversing a recent trend.

  • Spending on medicines rose 3.2 percent in the United States last year to $329.2 billion.

  • Final Glance: Biotechnology companies Monday, 14 Apr 2014 | 6:01 PM ET

    Amgen Inc. rose $1.38 or 1.2 percent, to $113.32. Biogen Idec rose $5.52 or 2.0 percent, to $279.52. Celgene Corp. rose $1.16 or. 8 percent, to $138.06.

  • Biotechs in the green after last week's carnage Monday, 14 Apr 2014 | 2:58 PM ET

    Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.

  • Midday Glance: Biotechnology companies Monday, 14 Apr 2014 | 2:08 PM ET

    Amgen Inc. rose $2.12 or 1.9 percent, to $114.06. Biogen Idec rose $6.40 or 2.3 percent, to $280.40. Celgene Corp. rose $1.64 or 1.2 percent, to $138.54.

Most Popular Video

Monday, 21 Apr 2014 | 12:02 AM ET

Simon Grose-hodge, Head of Investment Advisory, South Asia at LGT Bank Singapore, remains overweight on developed markets as the U.S. and Europe are showing signs of recovery.

Sunday, 20 Apr 2014 | 9:42 PM ET

Caroline Russell, CEO of Boh Plantations, speaks to CNBC's Julia Wood about the company's focus on maintaining dominance in its home market of Malaysia.

Sunday, 20 Apr 2014 | 8:47 PM ET

As the Beijing Auto Show kicks off on Monday, Martin Winterkorn, Chairman and CEO at Volkswagen, says plug-in hybrids will dominate its lineup in China for alternative energy cars.